JP2023512456A5 - - Google Patents

Info

Publication number
JP2023512456A5
JP2023512456A5 JP2022542692A JP2022542692A JP2023512456A5 JP 2023512456 A5 JP2023512456 A5 JP 2023512456A5 JP 2022542692 A JP2022542692 A JP 2022542692A JP 2022542692 A JP2022542692 A JP 2022542692A JP 2023512456 A5 JP2023512456 A5 JP 2023512456A5
Authority
JP
Japan
Prior art keywords
glycine
methionine
seq
combination
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022542692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512456A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/013074 external-priority patent/WO2021146191A1/en
Publication of JP2023512456A publication Critical patent/JP2023512456A/ja
Publication of JP2023512456A5 publication Critical patent/JP2023512456A5/ja
Pending legal-status Critical Current

Links

JP2022542692A 2020-01-13 2021-01-12 Il-7タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法 Pending JP2023512456A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062960593P 2020-01-13 2020-01-13
US62/960,593 2020-01-13
US202063108760P 2020-11-02 2020-11-02
US63/108,760 2020-11-02
US202063109475P 2020-11-04 2020-11-04
US63/109,475 2020-11-04
PCT/US2021/013074 WO2021146191A1 (en) 2020-01-13 2021-01-12 Method of treating a tumor with a combination of il-7 protein and a bispecific antibody

Publications (2)

Publication Number Publication Date
JP2023512456A JP2023512456A (ja) 2023-03-27
JP2023512456A5 true JP2023512456A5 (cg-RX-API-DMAC7.html) 2024-01-22

Family

ID=74562022

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542692A Pending JP2023512456A (ja) 2020-01-13 2021-01-12 Il-7タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法

Country Status (8)

Country Link
US (1) US20230057939A1 (cg-RX-API-DMAC7.html)
EP (1) EP4090430A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023512456A (cg-RX-API-DMAC7.html)
KR (1) KR20220150274A (cg-RX-API-DMAC7.html)
CN (1) CN114945409A (cg-RX-API-DMAC7.html)
AU (1) AU2021207586A1 (cg-RX-API-DMAC7.html)
IL (1) IL294663A (cg-RX-API-DMAC7.html)
WO (1) WO2021146191A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3146948A1 (en) * 2019-09-04 2021-03-11 Young Chul Sung Method for increasing lymphocyte count by using il-7 fusion protein in tumors
WO2023077136A1 (en) * 2021-10-29 2023-05-04 University Of Virginia Patent Foundation Bispecific antibodies

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
DK0482076T3 (da) 1989-07-14 1995-07-17 American Cyanamid Co Stabile vaccinepræparater indeholdende interleukiner
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5364612A (en) 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6730512B2 (en) 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CA2275539A1 (en) 1997-10-28 1999-05-06 Bando Chemical Industries, Ltd. A transdermal patch and a method for manufacture of a substrate sheet therefor
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
CA2343979C (en) 1998-09-21 2011-11-15 Schering Corporation Human interleukin-b50, therapeutic uses
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6749847B2 (en) 2000-03-30 2004-06-15 The University Of Connecticut Hybrid cytokine of IL-7 and β-chain of hepatocyte growth factor
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
EP1391513A1 (en) 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
US20050054054A1 (en) 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Il-7 융합 단백질
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
BRPI0510909A2 (pt) 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
EA016577B1 (ru) 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
BRPI0619331A2 (pt) 2005-10-26 2011-09-27 Medarex Inc método para fazer um composto para preparar um análogo de cbi cc-1065, método para preparar um análogo de cbi cc-1065 e composto
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
JP2010519310A (ja) 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
GB0815216D0 (en) 2008-08-21 2008-09-24 Asterion Ltd Interleukin
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
AU2011349049B2 (en) 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
EP4624490A3 (en) 2012-02-09 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
HK1256149A1 (zh) * 2015-06-11 2019-09-13 格纳西尼有限公司 经修饰的白细胞介素-7蛋白及其用途
US20190358258A1 (en) 2015-10-09 2019-11-28 Robert J. Deans Methods for enhancing proliferation of t regulatory cells
KR102386735B1 (ko) * 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
EP3431102A4 (en) * 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
KR102629905B1 (ko) * 2017-04-01 2024-01-30 베이징 한미 파마슈티컬 컴퍼니 리미티드 항-pd-l1/항-pd-1 천연 항체 구조-유사 헤테로다이머 이중특이성 항체 및 그의 제조
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ, インコーポレイテッド Hiv gp120およびcd3を標的とする多重特異性抗体
PH12021550661A1 (en) * 2018-09-26 2022-03-21 Astellas Pharma Inc Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy

Similar Documents

Publication Publication Date Title
May et al. Advances in bispecific biotherapeutics for the treatment of cancer
US20260102510A1 (en) Conditioning for in vivo immune cell engineering
Müller et al. Bispecific antibodies for cancer immunotherapy: Current perspectives
JP2021525731A5 (cg-RX-API-DMAC7.html)
CN104379601B (zh) 双特异性抗体分子和抗原-转染的t-细胞以及它们在医药中的用途
Moon et al. Development of bispecific antibody for cancer immunotherapy: focus on T cell engaging antibody
Maruani et al. A plug-and-play approach for the de novo generation of dually functionalized bispecifics
US10611814B2 (en) Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
JP2022545439A5 (cg-RX-API-DMAC7.html)
Thakur et al. Cancer therapy with bispecific antibodies: Clinical experience
AU2019286554A1 (en) Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2021144315A1 (en) Conjugates of antibodies an immune cell engagers
US20240197931A1 (en) Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells
Guo et al. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
TW201842182A (zh) 具抗原專一性的t細胞及其用途
JP2016514956A (ja) 免疫療法のためのエンゲージャー細胞
AU2018295119A1 (en) Multi-specific antibodies and methods of making and using thereof
US20180256744A1 (en) Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof
JP2022512891A5 (cg-RX-API-DMAC7.html)
JP2024519335A (ja) がん免疫療法のための投薬レジメン
Kelly et al. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct
JP2023512657A5 (cg-RX-API-DMAC7.html)
Wang et al. Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody
Ren‐Heidenreich et al. Redirected T‐cell cytotoxicity to epithelial cell adhesion molecule‐overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model
Li et al. Highlights of 2019 protein engineering summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic